Request Deal Involvement
Amryt Pharma completed the acquisition of Aegerion Therapeutics from Novelion Therapeutics for $400m.
Identify your role
Select the side you represented in this transaction, and provide your current job title.
Service Providers
financial advisors
Moelis & Co
financial advisors
AP Services
legal advisors
Willkie Farr & Gallagher
brokers
Shore Capital & Corporate
brokers
Davy Corporate Finance
pr advisors
Consilium Strategic Communications
brokers
Stifel
financial advisors
Shore Capital & Corporate
commercial advisors
LifeSci Partners
legal advisors
Gibson Dunn & Crutcher
financial advisors
MTS Securities
legal advisors
Norton Rose Fulbright
legal advisors
Goodwin Procter
financial advisors
Evercore
or
Principals
target
AEGERION PHARMACEUTICALS
bidder
AMRYT PHARMA PLC
vendor
NOVELION THERAPEUTICS
Principals or Service Provider not listed?Add missing Service Provider or Principal
Enter your Job Title on this deal
This title will appear on your profile next to this deal involvement.
To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:
All rights reserved. Copyright © 2025 Datasite